Drug Database
ME

metoclopramide (Gimoti / EVK 001 / EVK001)

✓ Approved

Evoke Pharma, Inc. · DRD2 · 小分子

什么是 metoclopramide?

metoclopramide 是一种小分子,由Evoke Pharma, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Intranasal、Oral (PO)。

药物档案

商品名Gimoti, EVK 001, EVK001
公司Evoke Pharma, Inc.
药物类别小分子
分子靶点DRD2, HTR4, PTGS1, PTGS2
给药途径Inhaled, Intranasal, Oral (PO)
状态Approved

作用机制

分子靶点

metoclopramide 作用于 4 个分子靶点:

DRD2dopamine receptor D2 (D2R, D2DR)
HTR45-hydroxytryptamine receptor 4 (5-HT4R, 5-HT4)
PTGS1prostaglandin-endoperoxide synthase 1 (PHS1, PGHS-1)
PTGS2prostaglandin-endoperoxide synthase 2 (COX2, COX-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

metoclopramide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastric atony✓ Approved

相关研究文献

PubMedAJE advances : research in epidemiology2026-11-19

Can self- or caregiver-administered nasal spray influenza vaccination improve outcomes? An agent-based model using the framework for reconstructing epidemiological dynamics.

Williams Katherine V KV, Nowalk Mary Patricia MP, Krauland Mary G MG, Mandell Alexis J AJ et al.

Newly licensed self- or caregiver-administered nasal spray live attenuated influenza vaccine (LAIV), available to order for home delivery, may improve vaccination coverage (VC) among adults aged 18-49 overall, as well as among those in this age group who live in households with school-aged children. Using the agent-based Framework for Reproducing Epidemiological Dynamics, which simulates influenza transmission in US census-based populations with defined household structures, we modeled the impact of: (1) 5%-15% VC increase among those aged 18-49 through self-administration and (2) household-based strategies for ages 5-17 and 18-49 that may occur from home LAIV orders. The household strategies included vaccinating children aged 5-17, followed by their 18-49-year-old head of household (HH) (kids + HH), and vaccinating children aged 5-17 and all household adults aged 18-49 (kids + adults). A 5%-15% VC increase in adults aged 18-49 reduced symptomatic cases in all adults by up to 10%. Among household strategies, kids + adults yielded a higher VC increase (9.2%) and greater reduction in symptomatic cases (5.7%) among adults ≥18 than the kids + HH strategy. The convenience of self-administration and household-based LAIV strategies in homes with school-age children may enhance adult VC and reduce influenza burden.

PMID 43053808
阅读全文 →
PubMedBMC anesthesiology2026-11-19

Modified nasopharyngeal airway device facilitates nasal fiberoptic intubation for trainee anesthesiologists: a randomized clinical study.

Vijitpavan Amorn A, Charoenkoop Poonyanuch P, Raksong Waralak W, Kitphasert Rachapha R

Fiberoptic nasotracheal intubation is an essential skill for anesthesiologists. Trainee anesthesiologists often face challenges due to the complex anatomy of the nasopharynx and the risk of upper airway collapse after anesthesia administration, which can lead to confusion and difficulty in identifying the glottic opening. This study evaluated whether a modified nasopharyngeal airway (mNPA) device can assist less experienced operators in performing nasal fiberoptic intubation on anesthetized patients with non-difficult airway. This randomized controlled trial analyzed 54 patients undergoing elective surgery with nasal intubation. The patients were then assigned to either the mNPA group (n = 28) or the conventional nasal fiberoptic intubation (cNFI) group (n = 26). In the mNPA group, a modified airway guided the flexible fiberoptic bronchoscope to the glottis, and the device was subsequently removed to facilitate intubation. Trainee anesthesiologists performed all intubations. The primary outcome was intubation time. The secondary outcomes included first-attempt success rate and bleeding complications. The mNPA group had a significantly faster vocal cord visualization time (11.49 vs. 47.56 s, P < 0.001) and a shorter intubation time (56.25 vs. 107.02 s, P < 0.001) than the cNFI group. The mNPA group had a significantly higher first-attempt success rate (96.43% vs. 73.08%, P value = 0.038) and a significantly lower incidence of blood staining in the periglottic area (3.57% vs. 26.92%, P value = 0.022) than the cNFI group. The mNPA significantly improved nasotracheal intubation time and success rates and reduced the number of attempts and bleeding complication rates for operators with limited experience in performing nasal fiberoptic intubation in non-difficult airway patients. Thai Clinical Trials Registry TCTR20230809006. Registered 9 August 2023.

PMID 43052804
阅读全文 →
PubMedInflammation2026-11-19

AURKA Contributes to Neutrophil Activation and NETosis in Chronic Rhinosinusitis with Nasal Polyps.

Tang Ru R, Wu Xiao X, Lai Yuxin Y, Liu Zhihan Z et al.

Neutrophil accumulation and neutrophil extracellular trap formation (NETosis) contribute to refractory chronic rhinosinusitis with nasal polyps (CRSwNP), yet targeted therapies remain limited. Aurora kinases (AURKs), classically known as cell-cycle regulators, have recently been implicated in immune modulation. This study investigated their involvement in CRSwNP-associated neutrophilic inflammation. Public single-cell RNA sequencing data were analyzed and validated in human nasal tissues. Multiplex immunofluorescence was used to define the cellular localization of AURKA and AURKB. Primary neutrophils were used to assess the effects of Aurora kinase inhibition on inflammatory activation, NET formation, and MAPK/NF-κB signaling. Intranasal Reversine was further evaluated in an LPS-induced neutrophilic chronic rhinosinusitis model. AURKA and AURKB were upregulated in CRSwNP tissues and positively associated with disease severity and inflammatory cell infiltration. AURKA showed a neutrophil-biased expression pattern and prominent localization in MPO⁺ neutrophils, whereas AURKB was more broadly distributed in epithelial cells and MBP⁺ eosinophils, with limited neutrophil expression. Reversine suppressed neutrophil activation, inflammatory cytokine expression, and NET formation, accompanied by reduced PADI4 expression and attenuated MAPK/NF-κB signaling pathway. Isoform-selective inhibition further showed that AURKA inhibition more effectively reduced neutrophil activation and NET-associated signaling than AURKB inhibition. Transcriptomic analysis confirmed that Reversine reduced pro-inflammatory and pro-NETotic signatures. In vivo, Reversine attenuated nasal mucosal inflammation, epithelial hyperplasia, neutrophil recruitment, NET formation, and inflammatory mediator expression. AURKA appears to be the predominant Aurora kinase associated with neutrophil activation and NETosis in CRSwNP-associated neutrophilic inflammation. Pharmacological Aurora kinase inhibition may represent a therapeutic strategy for refractory neutrophil-predominant CRSwNP.

PMID 43052578
阅读全文 →
PubMedBMC microbiology2026-11-19

Growth heterogeneity of Streptococcus suis in host-mimicking conditions is independent of clinical origin.

Perez-Falcón Ayelén A, Kochanowski Karl K, Florez-Sarasa Igor I, Feixes-Prats Elisenda E et al.

Streptococcus suis is an important swine and zoonotic pathogen whose virulence relies on complex, niche-specific metabolic adaptation within the host. However, the role of non-virulent S. suis strains in the host remains poorly understood. In this study, using host-mimicking media and biological fluids, we compared the growth of S. suis strains from different anatomical origins, including clinical isolates from diseased piglets and upper respiratory tract and vaginal isolates from healthy animals. Strains were evaluated in Todd-Hewitt Broth supplemented with yeast extract (THY), Human Plasma-Like Medium (HPLM), Synthetic Nasal Medium (SNM), and SNM supplemented with mucin (SNM + M). Most isolates exhibited robust growth in THY, whereas proliferation was reduced in HPLM and SNM. Notably, five isolates (two systemic, one nasal and two vaginal) displayed comparatively enhanced growth in SNM compared to the rest of the strains, although this phenotype was not associated with the anatomical origin of the strains. Mucin supplementation consistently increased growth across all tested isolates, suggesting that mucin availability may support S. suis proliferation under nutrient-limiting conditions. Experiments using biological fluids revealed that while all strains grew consistently in saliva, vaginal isolates showed comparatively reduced growth in vaginal fluid, indicating limited adaptation to this environment. No evidence of growth inhibition of virulent strains was observed during co-cultivation, while interactions were predominantly positive and influenced by nutrient availability. In summary, S. suis displays strain-specific variability in growth under different in vivo-like conditions independently of clinical origin. These findings suggest a role of metabolic adaptation in shaping bacterial fitness and highlight the importance of using host‑mimicking environments to uncover phenotypic differences and interactions masked under standard laboratory conditions.

PMID 43052736
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-11-18

Varenicline Nasal Spray for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: A Retrospective Study.

Zhang Yi-Jia YJ, Wang Gong-Yue GY, Tang Xue-Li XL, Xiao Yu-Ting YT et al.

To evaluate short-term post-dose and 4-week clinical changes in patients treated with varenicline nasal spray for dry eye disease (DED) associated with meibomian gland dysfunction (MGD). This retrospective study included 26 patients (26 eyes) with DED associated with MGD who received varenicline nasal spray between July and December 2025. Short-term post-dose changes were assessed by comparing measurements obtained before and 10 minutes after a single dose on Day -1. At least 24 hours later, Day 0 served as the longitudinal baseline, after which patients received one spray containing 0.03 mg in each nostril twice daily for 4 weeks. Outcomes included symptoms, tear-film parameters, corneal staining, meibomian gland measures, and the density of conjunctival goblet-cell-like structures assessed by in vivo confocal microscopy (IVCM). At 10 minutes post-dose, lipid layer thickness (LLT), non-invasive tear film break-up time (NIBUT), tear meniscus height, and anesthetized Schirmer test scores increased significantly (all P < 0.0001). At Week 4, mean paired changes were -21.43 points for OSDI (95% CI, -24.97 to -17.90), 28.19 nm for LLT (95% CI, 21.31-35.07), and 6.29 seconds for NIBUT (95% CI, 4.40-8.18; all P < 0.0001). Meibomian gland yielding scores increased and secretion scores decreased (both P < 0.0001), whereas gland dropout rates remained unchanged. IVCM-derived goblet-cell-like density increased by 138.04 cells/mm2 (95% CI, 105.62-170.45; P < 0.0001). No serious adverse events were documented; three patients experienced mild, transient nasal events. During 4 weeks of varenicline nasal spray treatment, improvements in dry eye symptoms, tear-film parameters, corneal staining, and meibomian gland functional measures, together with an increase in IVCM-observed conjunctival goblet-cell-like structures, were observed. These exploratory findings require confirmation in prospective, controlled, and longer-term studies.

PMID 43048565
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多metoclopramide